, Tracking Stock Market Picks
Enter Symbol:
Rating: BIOD
Mkt Outperform $3

BIODEL INC. (NASDAQ: BIOD) upgraded to Mkt Outperform with price target $3 by JMP Securities

Monday,  Apr 16, 2012  4:25 PM ET by Kristen Bailey

JMP Securities upgraded BIODEL INC. (NASDAQ: BIOD) to Mkt Outperform with
price target $3. JMP Securities rated BIODEL INC. (NASDAQ: BIOD) to Mkt Perform on 10/19/2010, when the price was $4.20.

Biodel Inc. (Biodel) is a development-stage specialty pharmaceutical company located in Danbury, Connecticut. The Company is focused on the development and commercialization of treatments for endocrine disorders, such as diabetes and osteoporosis. The Company develops product candidates by applying its formulation technologies to existing drugs in order to improve their therapeutic results. The Company?s initial development efforts are focused on peptide hormones. The Company?s advanced product candidate, VIAject, has been studied in two pivotal Phase III clinical trials for the treatment of patients with Type 1 and Type 2 diabetes. Earlier stage product candidates include VIAtab, a sublingual tablet formulation of insulin and two preclinical product candidates for the treatment of osteoporosis. The Company has developed all of its product candidates utilizing its VIAdel technology that allows the Company to study the interaction between peptide hormones and small molecules.

MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports. JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy